Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, TG Therapeutics Inc (NASDAQ: TGTX) closed at $31.67 down -4.78% from its previous closing price of $33.26. In other words, the price has decreased by -$4.78 from its previous closing price. On the day, 1.58 million shares were traded. TGTX stock price reached its highest trading level at $32.8 during the session, while it also had its lowest trading level at $31.61.
Ratios:
For a deeper understanding of TG Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.89 and its Current Ratio is at 3.82. In the meantime, Its Debt-to-Equity ratio is 0.42 whereas as Long-Term Debt/Eq ratio is at 0.42.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 24 ’25 when Echelard Yann sold 5,000 shares for $32.57 per share. The transaction valued at 162,850 led to the insider holds 223,816 shares of the business.
Echelard Yann bought 5,000 shares of TGTX for $162,850 on Nov 24 ’25. On Sep 11 ’25, another insider, Lonial Sagar, who serves as the Director of the company, sold 20,852 shares for $32.24 each. As a result, the insider received 672,268 and left with 94,061 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TGTX now has a Market Capitalization of 5027912192 and an Enterprise Value of 4753043968. As of this moment, TG’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.40, and their Forward P/E ratio for the next fiscal year is 17.32. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.08. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.45 while its Price-to-Book (P/B) ratio in mrq is 8.10. Its current Enterprise Value per Revenue stands at 8.936 whereas that against EBITDA is 46.224.
Stock Price History:
The Beta on a monthly basis for TGTX is 2.01, which has changed by -0.05151242 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, TGTX has reached a high of $46.48, while it has fallen to a 52-week low of $25.28. The 50-Day Moving Average of the stock is -6.39%, while the 200-Day Moving Average is calculated to be -9.31%.
Shares Statistics:
For the past three months, TGTX has traded an average of 1.97M shares per day and 1861860 over the past ten days. A total of 155.21M shares are outstanding, with a floating share count of 147.98M. Insiders hold about 6.79% of the company’s shares, while institutions hold 62.84% stake in the company. Shares short for TGTX as of 1763078400 were 25224861 with a Short Ratio of 12.80, compared to 1760486400 on 23810220. Therefore, it implies a Short% of Shares Outstanding of 25224861 and a Short% of Float of 20.78.
Earnings Estimates
Its stock is currently analyzed by 6.0 different market analysts. The consensus estimate for the next quarter is $0.33, with high estimates of $0.45 and low estimates of $0.23.
Analysts are recommending an EPS of between $3.09 and $2.44 for the fiscal current year, implying an average EPS of $2.87. EPS for the following year is $1.93, with 6.0 analysts recommending between $2.56 and $1.31.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $182.38M this quarter.It ranges from a high estimate of $189.3M to a low estimate of $176.9M. As of. The current estimate, TG Therapeutics Inc’s year-ago sales were $108.19MFor the next quarter, 8 analysts are estimating revenue of $197.69M. There is a high estimate of $209.5M for the next quarter, whereas the lowest estimate is $187.3M.
A total of 8 analysts have provided revenue estimates for TGTX’s current fiscal year. The highest revenue estimate was $613M, while the lowest revenue estimate was $600.6M, resulting in an average revenue estimate of $606.03M. In the same quarter a year ago, actual revenue was $329MBased on 8 analysts’ estimates, the company’s revenue will be $901.52M in the next fiscal year. The high estimate is $955.86M and the low estimate is $847.5M.
